Adyen partners with Limitless Technology Group to streamline payments across gifting brands

Adyen N.V. (ADYEN.AS) shares rose about 16% on Thursday after the company reported stronger H1 2026 results, with higher earnings and revenue growth, according to the company. The stock traded around 1,053.80 euros on the Amsterdam exchange, up 15.87% in the session, after opening at 962.00 euros.

Adyen shares rose about 12% to €1,019 after the Amsterdam-listed payments company reported first-half 2026 results: net revenue €1.30B (+19% YoY) and processed volume €803.8B (+24%). Adyen raised full-year 2026 constant-currency net revenue growth guidance to 21–23% and guided EBITDA margin about 1 point below 2025, citing acquisition integration costs. Analysts kept Outperform ratings with revised targets.

Adyen NV reported first-half results that beat expectations, citing higher payment volumes and merchant growth. Net revenue rose 19% to €1.30 billion and processed volume increased 24% to €803.8 billion. EBITDA was €641.5 million. Adyen kept its full-year outlook and guided 2026 net revenue growth of 21% to 23%, with 2026 capex about 7% of net revenue.

Adyen shares rose 2.8% to €886.6 after the Amsterdam-listed payments company said it will partner with Xiaomi to process payments in 18 markets using Adyen’s Unified Commerce for online and in-store transactions. The news comes amid 2026 pressure from a lowered revenue outlook, CFO departure, and analyst target cuts.

Cytokinetics (NASDAQ:CYTK) reported late-stage trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), meeting primary goals of improving symptoms and quality of life. The study showed 53% of patients on aficamten improved in key areas vs. 13% on placebo, but lacked significant structural or cardiovascular benefits. The company plans a US marketing application in Q4 2026. Analysts forecast peak sales of over $5 billion for Myqorzo, but investors expressed concerns over

Jefferies initiated coverage of Cameco (CCJ) and BWXT (BWXT) with 'Buy' ratings, setting price targets of $138 and $181 respectively, citing strong long-term prospects in nuclear energy. CCJ, a major uranium producer, and BWXT, a nuclear reactor provider, are positioned to benefit from global and U.S. initiatives to expand nuclear capacity. Both companies face risks, including uranium price volatility for CCJ and execution challenges for BWXT.